Ablynx

About:

Ablynx is a biopharmaceutical company engaged in the discovery and development of nanobodies.

Twitter/X: AblynxABLX

Top Investors: Jefferies, Alta Partners, SR One, Abingworth, Sofinnova Partners

Description:

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 projects in the pipeline and five Nanobodies in clinical development.

Total Funding Amount:

$499M

Estimated Revenue Range:

$50M to $100M

Headquarters Location:

Zwijnaarde, Oost-Vlaanderen, Belgium

Founded Date:

2001-01-01

Contact Email:

info(AT)ablynx.com

Founders:

Mark Vaeck

Number of Employees:

251-500

Last Funding Date:

2017-10-30

IPO Status:

Delisted

Industries:

Biopharma

Biotechnology

Pharmaceutical